Blog - Page 4092 of 5703

MondaySep 21, 2009 2:00 pm

Manhattan Scientifics Inc. (MHTX.OB) Inks Licensing Agreement with Carpenter Technology

Manhattan Scientifics Inc. capitalizes on inventions and technology by earning profits through licensing. It identifies, develops, patents, supports and markets these innovations to bring them into the marketplace. The company today announced an agreement with Carpenter Technology Corp. (NYSE: CRS) in which Carpenter will develop, manufacture and market a new class of high-strength metals under an exclusive license from Manhattan Scientifics and the Los Alamos National Laboratory. “Carpenter continues to forge ahead as the leading developer of stainless steels and specialty alloys,” Anne L. Stevens, Carpenter’s chairman and CEO stated in the press release. “Our relationship with Manhattan Scientifics will…

MondaySep 21, 2009 1:57 pm

Axial Vector Energy Corp. (AXVC.PK) Describes Dual Technologies of Petrosonics

Axial Vector Energy Corp., developer of advanced, high-efficiency energy engines, has access to two important fuel purification technologies associated with Petrosonics LLC, the privately held development stage oil refining technology company that is part of the PETROAVEC joint venture between Axial Vector and Petrosonics. The first technology uses ultrasound at moderate temperature and atmospheric pressure to reduce sulfur and nitrogen in processed diesel. This is important because there is worldwide legislation aimed at decreasing sulfur emissions to zero, including emissions from off-road use such as marine and locomotive. There is also a shift in demand from gasoline to diesel. Hydrotreatment,…

MondaySep 21, 2009 1:51 pm

Neuralstem, Inc. (CUR) Receives FDA Approval to Begin First ALS Stem Cell Trial

Neuralstem Inc. has patented technology which enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities. The company's technology also has the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The company is targeting major central nervous systems diseases such as Amyotrophic Lateral Sclerosis (ALS), better known as Lou Gehrig's disease. The company announced today that the US Food & Drug Administration (FDA) has approved its investigational new drug application to commence a Phase 1 trial to treat ALS or…

MondaySep 21, 2009 1:50 pm

Consorteum Holdings, Inc. (CSRH.OB) Sees Significant Opportunity in the United Arab Emirates

Consorteum Holdings Inc. is an international company focused on the financial services, payment and transaction processing industry. The company provides a unique long-range strategic plan that is tailored to a client's specific needs for electronic transaction and management services. Consorteum provides these services to a wide variety of private and public entities using the most technically advanced global solutions. The company is confident that they have spotted a significant growth opportunity in the United Arab Emirates (UAE). Consorteum believes there are unique factors at work in the UAE that may lead to exponential growth. One major factor is the expanding…

MondaySep 21, 2009 10:05 am

DOR BioPharma Inc. (DORB.OB) Earns $9.4 Million NIH Grant

DOR BioPharma Inc. is a late-stage biotechnology company that has been gaining national attention for its state-of-the-art technology. DOR reached a major milestone in the advancement of its company with the announcement that it has been awarded a $9.4 million grant from the National Institute of Allergy and Infectious Diseases, which is a division of the National Institute of Health (NIH). This grant will assist the company’s future over the next five years with the development of formulation and manufacturing processes for vaccines, including RiVax(TM), that are stable at elevated temperatures. The grant will also fund the development of improved…

MondaySep 21, 2009 9:59 am

GlaxoSmithKline (GSK) and XenoPort, Inc. (XNPT) Report Positive Results from Clinical Trial

Friday, GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (NASDAQ:XNPT) announced top-line results from a Phase II-b clinical trial. The study evaluates the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain, associated with post-herpetic neuralgia (PHN) in adults. The company reported that subjects were randomized to receive placebo, 1200, 2400 or 3600 mg/day of GSK1838262 dosed twice a day; all patients treated with GSK1838262 demonstrated statistically significant improvements over the control group. The primary endpoint was the change from baseline to the end of maintenance treatment in the 24-hour average pain intensity score. The 14-week, double-blind study enrolled 376 subjects with…

MondaySep 21, 2009 9:57 am

Speedus Corp. (SPDE) Subsidiary Receives Clearance to Market Signal X6 Device

Siemens Corporate Research spin-off and Speedus Corp. subsidiary, Zargis Medical Corp., announced Friday that it has received U.S. Food and Drug Administration clearance to market the new Signal X6(TM) device. The company also announced that seven Signal X6 devices have been delivered to the U.S. Army for deployment in six Department of Defense medical facilities. Signal X6 technology records heart and lung sounds from six adhesive sensors. The recordings can be evaluated locally or, when a cardiac specialist is not immediately available, transmitted through the Internet for remote evaluation. This feature makes the noninvasive technology easy to use. The configuration…

MondaySep 21, 2009 8:15 am

Clenergen Corp. (CRGE.OB) Appoints Dale Shepherd as CFO and Abillish Kamti as CFO of Clenergen India Private Ltd.

Chief Executive Mark Quinn announced this morning that the company has appointed Dale Shepherd as its Chief Financial Officer and Abillish Kamti as the Chief Executive of Clenergen India Private Ltd. Working from 1973 to 1991 for one of the world's premier global networks, the General Electric Company, Dale’s career has focused on hands on problem resolution, acquisitions, joint venture start ups and entering new business areas. During his time at GE, he held the positions of Director of Finance, GEM Polymers Ltd. Vice President, GE Plastics Japan Ltd. and Managing Director, GEM Chemicals, Inc. From there he joined Kawasaki…

MondaySep 21, 2009 8:03 am

Solanex Management, Inc. (SLNX.OB) Expands Previously Signed MOU for Oil Sand Extraction Technology

The Board of Solanex Management Inc. announced that Solanex has expanded the territories for the sub-license in their Memorandum of Understanding (MOU) for technology leasing rights for sales, marketing and distribution to a Pyrolitic Hydrocarbon Gasification System and a Liquid Extraction Systems. Additionally, the exclusive territories have been expanded to include the country of Mexico. With the terms and conditions for these rights remaining unchanged, this extension allows the company to explore opportunities in the extensive oil and used tire markets in Mexico. Government agencies throughout Mexico are all very concerned about environmental issues, especially as they pertain to used…

MondaySep 21, 2009 7:43 am

Muscle Flex Inc. (MFLI.PK) Announces Second Product Release; The Beagle StepFit(TM) Pedometer and the Beagle Mini

Muscle Flex Inc. was pleased to announce this morning the details of its second product release, The Beagle StepFit(TM) Pedometer (www.BeagleStepFit.com), a multi-functional pedometer. Clipping onto the waist of an individual for walking or running, the device provides the wearer with detailed information as to how many steps the person has taken as well as the distance traveled. In addition to these standard features, however, Muscle Flex has taken the pedometer one step further by including the following features: 1. Body Fat Monitor 2. Step Counter 3. Calorie Burn Counter 4. Distance Calculator 5. Exercise timer 6. Clock with Alarm:…

Site Search

Company Search